Jianguo Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jianguo Hong has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Tao Li
Department of General Surgery, QiLu Hospital, Shandong University, Jinan, Shandong, China
4 shared publications - Lun-Jie Yan
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China
3 shared publications - Zhao-Ru Dong
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China
3 shared publications - Kai-Xuan Liu
Department of General Surgery, QiLu Hospital, Shandong University, Jinan, Shandong, China
2 shared publications - Yu-Chuan Yan
Department of General Surgery, Qilu hospital, Shandong University, Jinan, China
2 shared publications - Zhiqiang Chen
Department of Hepatobiliary Surgery, General Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
2 shared publications
Latest Publications
- 29 June 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (5) , 1993-2008
Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis
Purpose Immune checkpoint inhibitors (ICIs) have been explored as first-line treatment in various types of previously untreatable malignancies, while limited evidence is available on the management of hepatitis B virus (HBV) in patients undergoing immunotherapy. We systematically reviewed data concerning challenges of hepatic adverse events including HBV reactivation and hepatitis in patients with chronic HBV infection undergoing immunotherapy. Methods A systematic search was conducted in Medline, web of science, Embase and Cochrane library up to May 31, 2022. Studies reporting the safety profile of ICIs in patients with HBV infection were eligible. Meta-analyses were conducted to generate odds ratios (ORs) with 95% confidence intervals (CIs). Results A total of 13 studies including 2561 patients were included for meta-analysis. The overall incidence rates of HBV reactivation in patients with chronic HBV infection and past HBV infection were 1.0% (95% CI 0–3%) and 0% (95% CI 0–0%), respectively. Among patients with chronic HBV infection, the incidence rates of HBV reactivation were 1.0% (95% CI 0–2%) and 10.0% (95% CI 4–18%) for patients with and without antiviral prophylaxis, respectively. Patients with chronic HBV infection were at a higher risk of HBV reactivation compared with those with past HBV infection [OR = 8.69, 95% CI (2.16–34.99)]. Antiviral prophylaxis significantly reduced the risk of HBV reactivation [OR = 0.12, 95% CI (0.02–0.67)] and HBV-associated hepatitis [OR = 0.05, 95% CI (0.01–0.28)] in patients with chronic HBV infection. Conclusions Prophylactic antiviral therapy should be administered to patients with chronic HBV infection undergoing anticancer immunotherapy. Patients with past HBV infection are at lower risk of HBV reactivation compared with those with chronic HBV infection, they could be initiated with antiviral prophylaxis or monitored with the intent of on-demand antiviral therapy.
- 29 June 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (5) , 1993-2008
Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis
Purpose Immune checkpoint inhibitors (ICIs) have been explored as first-line treatment in various types of previously untreatable malignancies, while limited evidence is available on the management of hepatitis B virus (HBV) in patients undergoing immunotherapy. We systematically reviewed data concerning challenges of hepatic adverse events including HBV reactivation and hepatitis in patients with chronic HBV infection undergoing immunotherapy. Methods A systematic search was conducted in Medline, web of science, Embase and Cochrane library up to May 31, 2022. Studies reporting the safety profile of ICIs in patients with HBV infection were eligible. Meta-analyses were conducted to generate odds ratios (ORs) with 95% confidence intervals (CIs). Results A total of 13 studies including 2561 patients were included for meta-analysis. The overall incidence rates of HBV reactivation in patients with chronic HBV infection and past HBV infection were 1.0% (95% CI 0–3%) and 0% (95% CI 0–0%), respectively. Among patients with chronic HBV infection, the incidence rates of HBV reactivation were 1.0% (95% CI 0–2%) and 10.0% (95% CI 4–18%) for patients with and without antiviral prophylaxis, respectively. Patients with chronic HBV infection were at a higher risk of HBV reactivation compared with those with past HBV infection [OR = 8.69, 95% CI (2.16–34.99)]. Antiviral prophylaxis significantly reduced the risk of HBV reactivation [OR = 0.12, 95% CI (0.02–0.67)] and HBV-associated hepatitis [OR = 0.05, 95% CI (0.01–0.28)] in patients with chronic HBV infection. Conclusions Prophylactic antiviral therapy should be administered to patients with chronic HBV infection undergoing anticancer immunotherapy. Patients with past HBV infection are at lower risk of HBV reactivation compared with those with chronic HBV infection, they could be initiated with antiviral prophylaxis or monitored with the intent of on-demand antiviral therapy.
- Open Access
- 17 January 2022
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 10 (5) , 835-846
Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis
Previous meta-analyses have shown that aspirin use may reduce the risk of hepatocellular carcinoma (HCC). However, the optimal dose, frequency, and duration of aspirin use or the safety and efficacy of aspirin in target populations for HCC prevention remain unclear. The study aim was to investigate the efficacy and safety of aspirin for prevention of HCC.
- 17 January 2022
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 10 (5) , 835-846
Open AccessEfficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis
Previous meta-analyses have shown that aspirin use may reduce the risk of hepatocellular carcinoma (HCC). However, the optimal dose, frequency, and duration of aspirin use or the safety and efficacy of aspirin in target populations for HCC prevention remain unclear. The study aim was to investigate the efficacy and safety of aspirin for prevention of HCC.
- Open Access
- 1 June 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (7) , 2258-2260
An Uncommon Lesion of the Liver
- 1 June 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (7) , 2258-2260
Open AccessAn Uncommon Lesion of the Liver
- Open Access
- 19 February 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis
Background and Aims: The clinical benefit of adjuvant antiviral therapy after curative therapy for HCC in patients with high preoperative HBV-DNA loads has been studied widely but that in patients with low preoperative HBV-DNA loads remains controversial. The purpose of this study was to determine the effect of antiviral treatment prophylaxis on HBV reactivation, overall survival (OS), and postoperative liver function in patients with low preoperative HBV-DNA levels undergoing curative resection.Methods: A meta-analysis was conducted by searching Web of Science, PubMed, Embase, and Cochrane Library until May 2020. We used REVMAN for data analysis and completed the study under the PRISMA guidelines.Results: Three randomized trials and seven cohort studies, comprising of 1,131 individuals, were included in the meta-analysis. Antiviral treatment significantly reduced the rate of HBV reactivation after curative treatment of HCC, with a pooled risk ratio of 0.12 (95% c.i. 0.07 to 0.21; P < 0.00001). The trials were consistently favorable for the antiviral group, with a pooled hazard ratio of 0.52 (95% c.i. 0.37 to 0.74; P = 0.0002) in respect of OS rate. However, by pooling the data from studies that reported ALT on the 30th day postoperatively, the result didn’t reach statistical significance (mean difference −4.38, 95% c.i. −13.83 to 5.07; P = 0.36). The I² values of the heterogeneity test for the above three comparisons are zero.Conclusion: Antiviral therapy during curative resection is effective in reducing HBV reactivation and improving OS rate in HCC patients with low viral load.
- 19 February 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessClinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis
Background and Aims: The clinical benefit of adjuvant antiviral therapy after curative therapy for HCC in patients with high preoperative HBV-DNA loads has been studied widely but that in patients with low preoperative HBV-DNA loads remains controversial. The purpose of this study was to determine the effect of antiviral treatment prophylaxis on HBV reactivation, overall survival (OS), and postoperative liver function in patients with low preoperative HBV-DNA levels undergoing curative resection.Methods: A meta-analysis was conducted by searching Web of Science, PubMed, Embase, and Cochrane Library until May 2020. We used REVMAN for data analysis and completed the study under the PRISMA guidelines.Results: Three randomized trials and seven cohort studies, comprising of 1,131 individuals, were included in the meta-analysis. Antiviral treatment significantly reduced the rate of HBV reactivation after curative treatment of HCC, with a pooled risk ratio of 0.12 (95% c.i. 0.07 to 0.21; P < 0.00001). The trials were consistently favorable for the antiviral group, with a pooled hazard ratio of 0.52 (95% c.i. 0.37 to 0.74; P = 0.0002) in respect of OS rate. However, by pooling the data from studies that reported ALT on the 30th day postoperatively, the result didn’t reach statistical significance (mean difference −4.38, 95% c.i. −13.83 to 5.07; P = 0.36). The I² values of the heterogeneity test for the above three comparisons are zero.Conclusion: Antiviral therapy during curative resection is effective in reducing HBV reactivation and improving OS rate in HCC patients with low viral load.
- 14 October 2020
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 29 (10) , E97-E99
Large low‐grade cystic pancreatic neuroendocrine neoplasm
A 58‐year‐old male was admitted to our hospital for a pancreatic cystic mass. Laboratory examination showed elevated levels of ALT (272 U/L, normal range, 9–50), AST (142 mg/L, normal range, 15–40), GGT (483 IU/ml, normal range, 10–60), AKP (542 U/L, normal range, 45–125), total bilirubin (21.9 U/L, normal range, 5–21), direct bilirubin (12.4 U/L, normal range, <6), CEA (7.21 ng/ml, normal range, 0–5), CA19‐9 (58.91 U/ml, normal range, 0–39) and NSE (24.16 ng/ml, normal range, 0–20).
- 14 October 2020
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 29 (10) , E97-E99
Large low‐grade cystic pancreatic neuroendocrine neoplasm
A 58‐year‐old male was admitted to our hospital for a pancreatic cystic mass. Laboratory examination showed elevated levels of ALT (272 U/L, normal range, 9–50), AST (142 mg/L, normal range, 15–40), GGT (483 IU/ml, normal range, 10–60), AKP (542 U/L, normal range, 45–125), total bilirubin (21.9 U/L, normal range, 5–21), direct bilirubin (12.4 U/L, normal range, <6), CEA (7.21 ng/ml, normal range, 0–5), CA19‐9 (58.91 U/ml, normal range, 0–39) and NSE (24.16 ng/ml, normal range, 0–20).
- 1 April 2019
- Published by Elsevier in Gastroenterology
- Vol. 156 (5) , e1-e3
Rare Multiple Lesions Arising in Small and Large Intestines
- 1 April 2019
- Published by Elsevier in Gastroenterology
- Vol. 156 (5) , e1-e3
Rare Multiple Lesions Arising in Small and Large Intestines
- 10 June 2018
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 33 (12) , 1940
Hepatobiliary and Pancreatic: Malignant pancreatic perivascular epithelioid cell tumor mimicking pancreatic neuroendocrine tumor
- 10 June 2018
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 33 (12) , 1940
Hepatobiliary and Pancreatic: Malignant pancreatic perivascular epithelioid cell tumor mimicking pancreatic neuroendocrine tumor